A recent study published in the journal Human Gene Therapy evaluated the long-term survival and cardiac efficacy of the gene ...

The Centers for Medicare & Medicaid Services Dec. 4 announced that drug manufacturers bluebird bio, inc. (manufacturer of ...

CMS has reached agreements with bluebird bio and Vertex Pharmaceuticals for their FDA-approved gene therapies for sickle cell disease — Casgevy and Lyfgenia, respectively.

Vertex Pharmaceuticals and bluebird bio have entered into an agreement with CMS to participate in a new Medicaid payment ...

Vertex Pharmaceuticals Inc. and bluebird bio Inc. — are the first to take part in a new Medicaid model intended to expand ...

The Centers for Medicare & Medicaid Services said on Wednesday it had entered into agreements with Vertex Pharmaceuticals and ...

Inhibiting TLR7, an immune signaling protein, may help preserve the protective layer surrounding nerve fibers in the brain during both Alzheimer's ...

Bluebird bio (BLUE) and Vertex (VRTX) have entered into outcome-based agreements with CMS aimed at expanding patient access ...

Gene Munster, Deepwater Asset Management managing partner, joins 'Squawk Box' to discuss Salesforce's Q3 results, the rise of ...

The Centers for Medicare & Medicaid Services has successfully negotiated agreements with two drug manufacturers to ...

Multiplexed assays of variant effect are an increasingly important tool in genetic research and including more context specificity in their design would aid interpretation and discovery.

Gene therapies can be life-changing for people, but the high cost plus the burden of treatment remain barriers to access and ...